ArticleGastroenterology research and practice2012
Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy.
Article in Gastroenterology research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication
Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis.World journal of gastroenterology · 2016Pooled it
- Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis.World journal of gastroenterology · 2015Pooled it
- Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis.World journal of gastroenterology · 2015Pooled it
- A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection.Medicine · 2015Trial
- Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication.World journal of gastroenterology · 2015Trial
- Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies forAntibiotics (Basel, Switzerland) · 2024Article
- Tailored eradication strategyWorld journal of gastroenterology · 2021Article
- In Vitro Screening Potential Antibacterial Properties of the Greek Oregano Honey against Clinical Isolates ofFoods (Basel, Switzerland) · 2021Article
- DNA vaccine containingIranian journal of basic medical sciences · 2021Article
- Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next?United European gastroenterology journal · 2021Article
- Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis.Journal of Korean medical science · 2016Observational
- Impact of Age, Gender, and Addition of Probiotics on Treatment Success for Helicobacter pylori in Children.Global pediatric health · 2015Article
- Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.World journal of gastroenterology · 2014Article
- Comparison between phenol red chromo-endoscopy and a stool rapid immunoassay for the diagnosis ofJournal of microscopy and ultrastructureArticle
- Hybrid therapy as first-line regimen forAnnals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the rising prevalence of antimicrobial resistance, the eradication rates of Helicobacter pylori (H. pylori) with standard treatments are decreasing to unacceptable levels (i.e., ≤80%) in most countries. After these disappointing results, several authorities have proposed that infection with H. pylori should be approached and treated as any other bacterial infectious disease. This implicates that clinicians should prescribe empirical treatments yielding a per protocol eradication of at least 90%. In recent years several treatments producing ≥90% cure rates have been proposed including sequential therapy, concomitant quadruple therapy, hybrid (dual-concomitant) therapy, and bismuth-containing quadruple therapy. These treatments are likely to represent the recommended first-line treatments in the near future. In the present paper, we are considering a series of critical issues regarding currently available means and approaches for the management of H. pylori infection. Clinical needs and realistic endpoints are taken into account. Furthermore, emerging strategies for the eradication of H. pylori and the existing evidence of their clinical validation and widespread applicability are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.